Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IP6K1 | Q92551 | 2/20 | 0.46 |
| ▸ | IP6K3 | Q96PC2 | 2/20 | 0.46 |
| ▸ | IP6K2 | Q9UHH9 | 1/20 | 0.46 |
| ▸ | F10 | P00742 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 2/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.33 |
| ▸ | BPTF | Q12830 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 6/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1860765 | 1.00 | IP6K1 (0.46) | IP6K1IP6K3IP6K2F10HTR6 | |
| SCHEMBL968073 | 0.80 | L3MBTL1 (0.44) | IP6K1F10MAPTKDM4EMEN1 | |
| SCHEMBL1858288 | 0.80 | L3MBTL1 (0.44) | IP6K1F10MAPTKDM4EMEN1 | |
| SCHEMBL5691206 | 0.79 | IP6K1 (0.48) | IP6K1IP6K3IP6K2HTR6AR | |
| SCHEMBL1863067 | 0.78 | KDM4E (0.41) | F10MAPTKDM4EMEN1ALDH1A1 | |
| SCHEMBL1857692 | 0.77 | USP2 (0.42) | F10MAPTKDM4EMEN1ALDH1A1 | |
| SCHEMBL1858169 | 0.76 | L3MBTL3 (0.55) | — | |
| SCHEMBL1240327 | 0.74 | LGMN (0.46) | MAPTKDM4EMEN1ALDH1A1CYP1A2 | |
| SCHEMBL1858163 | 0.74 | GRIN2B (0.49) | F10ESR1ESR2MAPTALDH1A1 | |
| SCHEMBL1856988 | 0.74 | F10 (0.36) | F10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8487116-B2 | Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBVIE INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-20120190845-A1 | FUSED COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ABBVIE INC. | 2012-07-26 | — | — | US | disclosed |
| US-8071762-B2 | Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBOTT LABORATORIES (US) | 2011-12-06 | — | — | US | disclosed |
| EP-2017265-B1 | Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBOTT LAB (US) | 2011-05-25 | — | — | EP | disclosed |
| EP-2017265-A1 | Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | Abbott Laboratories (US) | 2009-01-21 | — | — | EP | disclosed |
| US-20080287676-A1 | FUSED COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ABBOTT LABORATORIES (US) | 2008-11-20 | — | — | US | disclosed |
| EP-1658269-B1 | FUSED COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ABBOTT LAB (US) | 2008-10-22 | — | — | EP | disclosed |
| US-7375126-B2 | Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBOTT LABORATORIES (US) | 2008-05-20 | — | — | US | disclosed |
| EP-1658269-A1 | FUSED COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | Abbott Laboratories (US) | 2006-05-24 | — | — | EP | disclosed |
| US-20050043351-A1 | Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBVIE INC. | 2005-02-24 | — | — | US | disclosed |
| WO-2004111009-A1 | FUSED COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ABBOTT LABORATORIES (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287676-A1 | FUSED COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ARRB1, TRPV1, TRPV5 | IP6K1 1686/4885IP6K3 1763/4885IP6K2 1653/4885 |
| US-20050043351-A1 | Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ARRB1, TRPV1, TRPV5 | IP6K1 1662/4885IP6K3 1739/4885IP6K2 1636/4885 |
| US-20120190845-A1 | FUSED COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ARRB1, TRPV1, TRPV5 | IP6K1 1686/4885IP6K3 1763/4885IP6K2 1653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.